Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the... Ann Surg Oncol (2017) 24:2539–2546 DOI 10.1245/s10434-017-5863-x OR IG INA L A R TIC L E – BREA S T O NC OLOG Y Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) 1 2 2 3 4 Peter Beitsch, MD , Pat Whitworth, MD , Paul Baron, MD , Michael C. Rotkis, MD , Angela M. Mislowsky, MD , 5 6 7 8 Paul D. Richards, MD , Mary K. Murray, MD , James V. Pellicane, MD , Carrie L. Dul, MD , Charles H. Nash, 9 10 10 11 12 MD , Lisette Stork-Sloots, MSc , Femke de Snoo, MD, PhD , Sarah Untch, BS , and Laura A. Lee, MD 1 2 Targeted Medical Education, Dallas Breast Center, Dallas, TX; Targeted Medical Education, Nashville Breast Center, 3 4 Nashville, TN; Breast & Melanoma Specialists of Charleston, Charleston, SC; Northern Indiana Cancer Research 5 6 Consortium, South Bend, IN; Coastal Carolina Breast Center, Murrells Inlet, SC; Blue Ridge Cancer Care, Roanoke, VA; 7 8 9 Cleveland Clinic Akron General, Akron, OH; Virginia Breast Center, Bon Secours Cancer Institute, Richmond, VA; St. 10 11 John Region, Grosse Pointe Woods, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Surgical Oncology Springer Journals

Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

Loading next page...
1
 
/lp/springer_journal/pertuzumab-trastuzumab-ct-versus-trastuzumab-ct-therapy-for-her2-qu6SVdcd2H

References (15)

Publisher
Springer Journals
Copyright
Copyright © 2017 by Society of Surgical Oncology
Subject
Medicine & Public Health; Surgical Oncology; Oncology; Surgery
ISSN
1068-9265
eISSN
1534-4681
DOI
10.1245/s10434-017-5863-x
pmid
28447218
Publisher site
See Article on Publisher Site

Abstract

Ann Surg Oncol (2017) 24:2539–2546 DOI 10.1245/s10434-017-5863-x OR IG INA L A R TIC L E – BREA S T O NC OLOG Y Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) 1 2 2 3 4 Peter Beitsch, MD , Pat Whitworth, MD , Paul Baron, MD , Michael C. Rotkis, MD , Angela M. Mislowsky, MD , 5 6 7 8 Paul D. Richards, MD , Mary K. Murray, MD , James V. Pellicane, MD , Carrie L. Dul, MD , Charles H. Nash, 9 10 10 11 12 MD , Lisette Stork-Sloots, MSc , Femke de Snoo, MD, PhD , Sarah Untch, BS , and Laura A. Lee, MD 1 2 Targeted Medical Education, Dallas Breast Center, Dallas, TX; Targeted Medical Education, Nashville Breast Center, 3 4 Nashville, TN; Breast & Melanoma Specialists of Charleston, Charleston, SC; Northern Indiana Cancer Research 5 6 Consortium, South Bend, IN; Coastal Carolina Breast Center, Murrells Inlet, SC; Blue Ridge Cancer Care, Roanoke, VA; 7 8 9 Cleveland Clinic Akron General, Akron, OH; Virginia Breast Center, Bon Secours Cancer Institute, Richmond, VA; St. 10 11 John Region, Grosse Pointe Woods,

Journal

Annals of Surgical OncologySpringer Journals

Published: Apr 26, 2017

There are no references for this article.